B. Riley Wealth Advisors’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

B. Riley Wealth Advisors’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,873	Closed	-$233K	–	915
2019 Q4	$233K	Buy	+1,873	New	+$168K	0.02%	710
2015 Q1	–	Sell	-4	Closed	-$1	–	2113
2014 Q4	$1	Buy	+4	New	+$739	﹤0.01%	3601
2014 Q3	–	Sell	-90	Closed	-$21.3K	–	1996
2014 Q2	$21.3K	Buy	+90	New	+$23.7K	0.01%	1443

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

B. Riley Wealth Advisors's ICPT Position: Q1 2020 in Review

B. Riley Wealth Advisors sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2020, closing a stake of 1,873 shares — an estimated $233K sold.

B. Riley Wealth Advisors first reported a position in ICPT in Q2 2014 and held it in 3 quarters. The position peaked at $233K in Q4 2019. 188 funds tracked by Wall St. Rank hold ICPT as of Q1 2020.

B. Riley Wealth Advisors reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
B. Riley Wealth Advisors sold 1,873 Intercept Pharmaceuticals, Inc. shares in Q1 2020, an estimated $233K.
B. Riley Wealth Advisors first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2014 and held it in 3 quarters.
B. Riley Wealth Advisors's Intercept Pharmaceuticals, Inc. position peaked at $233K in Q4 2019.
188 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2020.

Based on B. Riley Wealth Advisors's 13F filing for Q1 2020, filed 6 May 2020.